Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells
Authors:
- 30 May 2017
- journal article
- other
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 59 (1) , 196-203
Abstract
Angiogenesis and JAK2 V617F mutation are common in BCR-ABL1 negative myeloproliferative neoplasms (MPNs). Ruxolitinib, a JAK inhibitor, is an effective treatment for some MPNs. However, the relationship between angiogenesis and JAK2 V617F and the effects of ruxolitinib on angiogenesis are still unknown. Here, we observed the correlation of JAK2 V617F mutation burden with VEGF, HIF-1a and microvascular density (MVD) in MPNs. We investigate the effect of ruxolitinib on the expression of VEGF and HIF-1α in JAK2 V617F positive cells. We found the expression levels of p-JAK2, VEGF, HIF-1a and MVD in the newly diagnosed MPNs were significantly increased and were related to the JAK2 V617F burden. Ruxolitinib can inhibit p-JAK2, VEGF, HIF-1a expression and suppress blood vessels’ formation in chick embryo choriallantoic membrane. Our findings indicated that angiogenesis is related to JAK2 V617F burden and ruxolitinib could decrease VEGF and HIF-1a expression in JAK2 V617F positive cells.Keywords
Funding Information
- Hebei Province Science and Technology Support Program (162777120D)
- Hebei Provincial Fund on Science and Technology, China (162777120D)
This publication has 23 references indexed in Scilit:
- Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinibLeukemia Research, 2014
- Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myelomaAngiogenesis, 2013
- Increased Angiogenesis-associated Poor Outcome in Acute Lymphoblastic LeukemiaApplied Immunohistochemistry & Molecular Morphology, 2012
- Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy andJAK2–V617Fmutational statusLeukemia & Lymphoma, 2010
- Angiogenesis and vascular endothelial growth factor‐/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2‐V617F mutational statusBritish Journal of Haematology, 2009
- Antiangiogenesis in haematological malignanciesBritish Journal of Haematology, 2008
- Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlationsBritish Journal of Haematology, 2007
- Hypoxia Inducible Factor-1–Independent Pathways in Tumor AngiogenesisClinical Cancer Research, 2007
- Activation of the HIF pathway in childhood ALL, prognostic implications of VEGFLeukemia, 2004
- Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and Myelofibrosis Has an Increased VascularityThe American Journal of Pathology, 2000